Despite J&J’s Woes, Wall Street Sees Turnaround In Pharma Business
Executive Summary
Johnson & Johnson’s pharma business appears to be weathering headwinds that are hobbling its consumer and medical device sales. Pharma accounted for 36% of JNJ’s 2010 sales of $61.6 billion.